200 related articles for article (PubMed ID: 32072585)
1. Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017.
Lee SW; Park SH; Song I; Noh Y; Park H; Ha D; Shin JY
Ther Innov Regul Sci; 2020 Mar; 54(2):418-423. PubMed ID: 32072585
[TBL] [Abstract][Full Text] [Related]
2. Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States.
Cho I; Han E
Int J Environ Res Public Health; 2022 Mar; 19(5):. PubMed ID: 35270550
[TBL] [Abstract][Full Text] [Related]
3. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
Tsuji K; Tsutani K
J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
[TBL] [Abstract][Full Text] [Related]
4. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
Nakayama H; Matsumaru N; Tsukamoto K
Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Pediatric Drug Approval Lag in Japan.
Ueyama E; Kaneko M; Narukawa M
Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials.
Ushijima S; Matsumaru N; Tsukamoto K
Pharmaceut Med; 2021 Jul; 35(4):253-260. PubMed ID: 34291425
[TBL] [Abstract][Full Text] [Related]
7. Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020.
Choi H; Lee H; Park B; Kim C; Lee J
Ther Innov Regul Sci; 2023 May; 57(3):552-560. PubMed ID: 36539577
[TBL] [Abstract][Full Text] [Related]
8. Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea.
Shih YR; Liao KH; Chen YH; Lin FJ; Hsiao FY
Clin Transl Sci; 2020 Sep; 13(5):916-922. PubMed ID: 32166908
[TBL] [Abstract][Full Text] [Related]
9. Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis.
Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
Clin Pharmacol Ther; 2021 May; 109(5):1265-1273. PubMed ID: 33048367
[TBL] [Abstract][Full Text] [Related]
10. Oncology drug lag in Japan: has it improved over the last decade?
Tachibana Y; Narukawa M
Int J Clin Oncol; 2023 Nov; 28(11):1451-1460. PubMed ID: 37561368
[TBL] [Abstract][Full Text] [Related]
11. Delay in Vaccine Access in ASEAN Countries.
Subsittipong N; Choi J; Kim TH; Han E
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409470
[TBL] [Abstract][Full Text] [Related]
12. Lag Time for New Innovative, First-in-Class, Drug Approval in Japan.
Miyazaki T; Komiyama M; Matsumaru N; Maeda H; Tsukamoto K
Biol Pharm Bull; 2022; 45(4):477-482. PubMed ID: 35370272
[TBL] [Abstract][Full Text] [Related]
13. The notorious "drug lag" for oncology drugs in Japan.
Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
[TBL] [Abstract][Full Text] [Related]
14. International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea.
Shin EY; Hong YJ; Lim KM; Kim TH; Lee JH
J Pharm Policy Pract; 2024; 17(1):2354299. PubMed ID: 38845625
[TBL] [Abstract][Full Text] [Related]
15. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?
Maeda H; Kurokawa T
Int J Clin Oncol; 2015 Dec; 20(6):1072-80. PubMed ID: 25837976
[TBL] [Abstract][Full Text] [Related]
16. Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan.
Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
Br J Clin Pharmacol; 2021 Aug; 87(8):3279-3291. PubMed ID: 33511674
[TBL] [Abstract][Full Text] [Related]
17. Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US.
Maki A; Narukawa M
Ther Innov Regul Sci; 2023 Jul; 57(4):671-677. PubMed ID: 36966205
[TBL] [Abstract][Full Text] [Related]
18. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
Kawabata-Shoda E; Masuda S; Kimura H
J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
[TBL] [Abstract][Full Text] [Related]
19. [Delays in clinical development of neurological drugs in Japan].
Ikeda M
Rinsho Shinkeigaku; 2017 Jun; 57(6):274-279. PubMed ID: 28552868
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of drugs approved in Japan without conducting confirmatory clinical trials.
Izuka S; Matsumaru N; Tsukamoto K
J Clin Pharm Ther; 2021 Dec; 46(6):1582-1590. PubMed ID: 34250620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]